Evidence map›Paper›PMID 41847089›Full record

ReviewPeerJ2026

Gut microbiota dysbiosis and the gut-lung axis: links to asthma and its common comorbidities.

Jianyu Xie, Jianwei Yu

Abstract readReview
In one paragraph

Review in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jianyu XieJiangxi University of Traditional Chinese Medicine, Nanchang, China.
Jianwei YuJiangxi University of Traditional Chinese Medicine, Nanchang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asthma is a heterogeneous chronic inflammatory airway disease that frequently coexists with multiple comorbidities, including obesity, allergic rhinitis, chronic rhinosinusitis, and gastroesophageal reflux disease (GERD). These conditions substantially increase disease burden and complicate asthma management. Increasing evidence suggests that gut microbiota dysbiosis represents a shared biological factor linking asthma and its comorbidities through immune and metabolic pathways operating along the gut-lung axis. This narrative review summarizes current knowledge on how alterations in gut microbial composition and function influence immune homeostasis, chronic inflammation, and disease susceptibility in asthma and its common comorbid conditions. Particular emphasis is placed on microbial metabolites such as short-chain fatty acids, early-life immune programming, bidirectional gut-lung immune communication, and emerging microbiota-targeted interventions. Understanding the systemic role of the gut microbiota may provide novel insights into integrated prevention and management strategies for asthma and its comorbidities.

Indexed as

AsthmaDysbiosisGastrointestinal MicrobiomeLungComorbidityGastroesophageal RefluxHumansObesityRhinosinusitisAllergic rhinitisAsthmaChronic rhinosinusitisGastroesophageal refluxGut microbiotaObesity

Identifiers

PMID41847089
PMCPMC12990899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.